PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

European Mass Spectrometry Markets Show Promising Growth Due to Increased Awareness - The European mass spectrometry (MS) markets face a range of challenges such as product pricing and limited funding from the private sector
European Mass Spectrometry Markets Show Promising Growth Due to Increased Awareness

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/03/25 - The European mass spectrometry (MS) markets face a range of challenges such as product pricing and limited funding from the private sector.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

However, technological advances, mounting awareness of their role in clinical diagnostics and a widening application base are set to promote the uptake of MS instruments over the next few years.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), Opportunities for the European Mass Spectrometry Market in Clinical Applications, finds that the market earned revenues of $562.0 million in 2007 and estimates this to reach $1,078.8 million in 2014.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the opportunities for European mass spectrometry market in clinical applications, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com. Include your full name, company name, title, telephone number, company email address, company website, city, state and country, and an overview will be sent to you by email upon receipt of the above information.

"The European MS markets will be driven by the ongoing implementation of competitive strategies, including the hybridisation of existing spectrometric techniques (Tandem MS) for accurate throughput results," notes Frost & Sullivan Research Analyst Suraj Ramanathan. "In the clinical diagnostic sector, areas such as biomarker identification and automated genotyping have exhibited a phenomenal increase in the usage of hybrid MS instruments."

Currently, Tandem MS is the most powerful tool in the identification of peptides and proteins for proteomics and drug discovery research. With higher resolution and accuracy standards being of prime importance for researchers and physicians, hybrid MS systems offer a potential strategy to attain greater market presence.

One of the most important challenges faced by market participants relates to the stabilisation of product pricing. R&D costs tend to be extremely high. Therefore, to recoup their outlay and make sizeable profits, manufacturers are compelled to price their instruments at relatively high levels.

"To make adequate returns after incurring expenditure on various external factors such as production, sales and marketing, manufacturers are being forced to increase the price of such analytical instruments," adds Ramanathan. "In turn, researchers are having to compromise on their funds to obtain quality data coupled with faster throughput results."

To succeed in this market, companies should form favourable partnerships, alliances or investigate mergers and acquisitions. Owing to the rising R&D investments in life sciences and bioinstrumentation, market participants stand to benefit by merging or partnering with other companies, thereby reducing their expenditure. Other advantages of this strategy include an exchange of basic technology and building a broader customer base, together with a stronger sales and distribution network.

Opportunities for the European Mass Spectrometry Market in Clinical Applications is part of the Drug Discovery Technologies Growth Partnership Services Programme, which also includes research in the following markets: European Molecular Diagnostics Markets, European IVD Market, European Cancer Diagnostic Market and European Primary Care Diagnostics. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Opportunities for the European Mass Spectrometry Market in Clinical Applications - M207

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


European Mass Spectrometry Markets Show Promising Growth Due to Increased Awareness

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)